GSK plc

Congress: 1 buys, 2 sells (3 total trades)

INTELLIGENT CROSS LLC

UBS ATS

LEVEL ATS

MS TRAJECTORY CROSS (ATS-1)

Dilution score: 12/100 (LOW), None months cash

13F fund flow: neutral, 35 institutional managers

Arrowstreet

Point72

DE Shaw

Acadian

Fisher Investments

Capital Research

Hudson Bay

ExodusPoint

Dodge & Cox

Balyasny

227 PubMed publications found for GSK plc

Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer.

Developing low-carbon salbutamol MDI: assessment of relative bioavailability and pharmacodynamic relative potency of salbutamol MDI with propellant HFA-152a.

Effects of anti-inflammatory agents on cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials.

Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules.

Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B).

Short interest: ?% of float, squeeze risk: MODERATE

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="GSK">
<p>GSK plc (GSK) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for GSK were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001131399 (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22GSK%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0001131399

GSK plc (GSK) — BioTechSigns Verified Summary

GSK plc (GSK) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for GSK were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0001131399. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22GSK%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17